Michael J. Malinowski

Personal Genome Medicine (eBook, PDF)

• Format: PDF

Produktbeschreibung

In the years following FDA approval of direct-to-consumer, genetic-health-risk testing, millions of people in the United States have sent their DNA to companies to receive personal genetic health risk information without physician or other learned medical professional involvement. In Personal Genome Medicine, Michael J. Malinowski examines the ethical, legal, and social implications of this development. Drawing from the past and present of medicine in the U.S., Malinowski applies law, policy, public and private sector practices, and governing norms to analyze the commercial personal genome sequencing and testing sectors and to assess their impact on the future of U.S. medicine. Written in relatable and accessible language, the book also proposes regulatory reforms for government and medical professionals that will enable technological advancements while maintaining personal and public health standards.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Cambridge University Press
• Erscheinungstermin: 31. August 2023
• Englisch
• ISBN-13: 9781009293372
• Artikelnr.: 68995202

Autorenporträt

Michael J. Malinowski is the Ernest R. and Iris M. Eldred Endowed Professor of Law and the Lawrence B. Sandoz Jr. Endowed Professor of Law at the Paul M. Hebert Law Center, Louisiana State University. He has published extensively on biotechnology research and development (R&D), health care, and bioethics.

Inhaltsangabe

Prologue: revolution, transition and transformation; 1. Medical profession
sovereignty to protect and promote the science and evidence base of US
medicine; 2. US integration of government, academia and industry: a
catalyst for science-technology revolutions; 3. The proliferation of US
Direct-to-Consumer (DTC) and Direct-to-Physician (DTP) biopharmaceutical
marketing; 4. The evolution of consumer genetic testing services from
Oncormed, Inc. to 23andMe Holding Co.; 5. Vulnerability of the science and
evidence base of US medicine; 6. A warning label for commercial
Direct-to-Consumer (DTC) genetics; 7. Protecting and promoting the
evidentiary-science base of Personal Genome Medicine (PGM); Epilogue: the
personal genome future of US medicine.